Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0933 • ACR Convergence 2024
NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils
Teneema Kuriakose, Mingxin Yang, Lacie Scaletta and Gary Sims, Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: Autoantibodies targeting citrullinated proteins (ACPAs) are a characteristic feature and a diagnostic marker in rheumatoid arthritis (RA). The generation of citrullinated protein autoantigens is…
Abstract Number: 0980 • ACR Convergence 2024
Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort
Jiayi Zheng¹, Nevena Barjaktarovic² and Liangjing lu³, ¹Washington University School of Medicine, St. Louis, MO, ²The Wright Center for Community Health, South Abington Township, PA, ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: Ambient air pollution is a mixture of solid particles and gaseous pollutants derived from fossil fuel combustion and vehicle exhaust. Previous research has linked…
Abstract Number: 1037 • ACR Convergence 2024
Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review
Alice Terrett¹, Athena Chin², Mihye Kwon³, Samuel Whittle⁴ and Catherine Hill⁵, ¹The Queen Elizabeth Hospital, Adelaide, Australia, ²Royal Adelaide Hospital, Tranmere, South Australia, Australia, ³Konyang University, College of Medicine, Daejeon, Republic of Korea, ⁴The Queen Elizabeth Hospital, Springfield, South Australia, Australia, ⁵The Queen Elizabeth Hospital, Woodville, South Australia, Australia
Background/Purpose: The use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), has significantly improved disease and functional…
Abstract Number: 1246 • ACR Convergence 2024
Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies
Alessandro Giollo¹, Mariangela Salvato², Margherita Zen³ and doria Andrea⁴, ¹Azienda Ospedale Università Padova, Padova, Padua, Italy, ²University of Padua, Padova, Italy, ³University of Padova, Padova, Padua, Italy, ⁴University of Padova, Padova, Italy
Background/Purpose: To explore the influence of the rheumatologist's sex on long-term outcomes in patients with rheumatoid arthritis (RA) undergoing biologic therapy.Methods: This is a prospective,…
Abstract Number: 1336 • ACR Convergence 2024
Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³ and Masayoshi Harigai⁴, ¹Meiji Pharmaceutical University, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Showa University, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, there are concerns about the risk of malignancy…
Abstract Number: 1352 • ACR Convergence 2024
The Associations Between Genetic Factors and Rheumatoid Arthritis Treatment Patterns: Data from Two Large Healthcare Systems
Gregory McDermott¹, Xin Xiong², Rachel Knevel³, Jing Cui⁴, Mary Jeffway⁴, Vidul Panickan⁵, Andrew Cagan⁴, Rahul Sangar⁶, Daniel Posner⁶, Lauren Costa⁶, Rachael Matty⁶, Elizabeth Karlson⁴, Yuk-Lam Ho⁶, Kelly Cho⁶, Rui Duan², Tianxi Cai² and Katherine Liao⁴, ¹Brigham and Women's Hospital, Brookline, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Harvard Medical School, Boston, MA, ⁶U.S. Department of Veterans Affairs, Boston, MA
Background/Purpose: In a prior study, we described an alternative method for subphenotyping RA patients by the sequence of biologic DMARDs (bDMARDs) they receive over time.…
Abstract Number: 1369 • ACR Convergence 2024
Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset
Peter Youssef¹, Sabina Ciciriello², Talib Tahir³, Tegan Smith⁴, Catherine O'Sullivan⁴, Joanna Leadbetter⁵, Belinda Butcher⁵, Nicole Walsh⁶, Miriam Calao⁶ and Geoffrey Littlejohn⁷, ¹Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, ²The University of Melbourne, Melbourne, Victoria, Australia, ³Coburg Rheumatology Service, Coburg, Victoria, Australia, ⁴OPAL Rheumatology Ltd, Geelong, Victoria, Australia, ⁵WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁶AbbVie Pty Ltd, Mascot, New South Wales, Australia, ⁷Monash University, Clayton, Victoria, Australia
Background/Purpose: To describe the real-world treatment patterns, response and persistence in rheumatoid arthritis (RA) patients (pts) treated with upadacitinib (UPA).Methods: This retrospective, non-interventional, multicenter cohort…
Abstract Number: 1386 • ACR Convergence 2024
Olokizumab in Real Clinical Practice: Efficacy and Safety
Sofia Kuzkina¹, Alena Zagrebneva², Galym Togizbayev³, Elvira Aitova⁴, Nataliya Belozerova⁵, Irina Patrikeeva⁶, Ruzana Samigullina⁷, Mikhail Sostak⁷, Evgeniya Jakovleva⁸, Anton Chudinov⁹, Antonina Dolgorukova¹⁰, Evgeniy Alekseev¹¹ and EVGENY NASONOV¹², ¹R-Pharm, Moscow, Russia, ²Clinical hospital #52, Moscow, Russia, ³Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, ⁴Clinic of Bashkir State Medical University, Ufa, Russia, ⁵SBIHC «Region clinic hospital Nr 2»; SBEA HE «Kuban state medical university»,, Krasnodar, Russia, ⁶GBUZ Tyumen Regional Clinical Hospital N 1, Tyumen, Russia, ⁷North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia, ⁸Scientific Research Institute - Ochapovsky Regional Clinical Hospital no. 1, Krasnodar, Russia, ⁹Clinical Rheumatology Hospital No.25; North-West State Medical University named after I.I.Mechnikov, Saint-Petersburg, Russia, ¹⁰R-Pharm, JSC, Moscow, Russia, ¹¹R-Pharm, JSC, Saint-Petersburg, Russia, ¹²V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Background/Purpose: Olokizumab (OKZ) is a direct inhibitor of interleukin 6, which has shown significant symptom reduction in RA patients, however there is a lack of…
Abstract Number: 1403 • ACR Convergence 2024
Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center
MANJIT SALUJA¹ and ARVIND CHOPRA², ¹CENTER FOR RHEUMATIC DISESAES, Pune, Maharashtra, India, ²CENTER FOR RHEUMATIC DISEASES, Pune, Maharashtra, India
Background/Purpose: Our patients often express concerns related to ‘wellbeing’ that are not routinely attended during standard care (including QOL). Alternatively, these concerns are important components…
Abstract Number: 1681 • ACR Convergence 2024
Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study
Anna Zubrzycka-Sienkiewicz¹, Kamilla Klama², Martin Ullmann³, Corinne Petit-Frere³, Andras Illes³, Olga Menang³, Joëlle Monnet³ and Peter Baker³, ¹Reumatika - Centrum Reumatologil", NZOZ, Warszawa, Poland, ²Solumed Centrum Medyczne, Poznań, Poland, ³Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland
Background/Purpose: A therapy transition from the originator to a biosimilar offers significant advantages for patients by lowering medication costs and improving accessibility to treatments. MSB11456…
Abstract Number: 1845 • ACR Convergence 2024
Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis
Amy Anderson¹, Luke Jones², Fiona Rayner³, Jessica Swift¹, Daniel Maunder¹, Henrique de Paula Lemos¹, David Swan⁴, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Gary Reynolds¹, Jasmine Sim¹, Andrew Melville⁵, Stefan Siebert⁵, Iain McInnes⁶, Carl Goodyear⁵, Catharien Hilkens¹, Karim Raza⁷, Christopher Buckley⁸, Kenneth Baker¹, Arthur Pratt³, Andrew Filer⁷ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, Birmingham, United Kingdom, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, ⁵School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁷Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁸Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Understanding the mechanisms that drive disease flares in patients with rheumatoid arthritis (RA) may aid in the development of biomarkers to facilitate targeted treatment…
Abstract Number: 1903 • ACR Convergence 2024
Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX
Vijaya Rivera Teran¹, David Vega Morales², Iris Jazmín Colunga Pedraza³, Sandra Sicsik Ayala⁴, Angel Alejandro Castillo Ortiz⁵, Miguel Angel Saavedra Salinas⁶, Dafhne Miranda Hernández⁷, Fedra Irazoque Palazuelos⁸, Julio César Casasola Vargas⁹, Omar Eloy Muñoz Monroy¹⁰, Sandra Carrillo Vazquez⁸, javier Merayo Chalico¹¹, Guillermo Guaracha Basañez¹², Estefania Torres Valdez¹³, Luis Valdés Corona¹⁴, Angélica Peña Ayala¹⁵, Sergio Durán Barragán¹⁶, Azucena Ramos Sánchez², Aleni Paz Viscarra¹⁴, Erick Adrián Zamora Tehozol¹⁷, Daniel Xibillé Friedman¹⁸ and Jiram Torres Ruiz¹⁹, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Instituto Mexicano del Seguro Social, Monterrey, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Instituto Mexicano del Seguro Social, Torreón, Mexico, ⁵Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Merida, Mexico, ⁶División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ⁷Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁸Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, ⁹Hospital General de México, “Dr.Eduardo Liceaga”, MEXICO CITY, Mexico, ¹⁰Hospital Central Militar, Mexico City, Mexico, ¹¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, ¹³Instituto Mexicano del Seguro Social, Querétaro, Mexico, ¹⁴Práctica Privada, Mexico City, Mexico, ¹⁵Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Ciudad de Mexico, Distrito Federal, Mexico, ¹⁶Clínica de Investigación en Reumatología, Guadalajara, Mexico, ¹⁷Práctica Privada, Merida, Mexico, ¹⁸Práctica Privada, Cuernavaca, Mexico, ¹⁹INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: To evaluate the impact of multimorbidity on the effectiveness of targeted synthetic and biologic disease-modifying antirheumatic drug (ts/bDMARD), in patients with rheumatoid arthritis in a two-year follow-up.Methods:…
Abstract Number: 2118 • ACR Convergence 2024
Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis
Yen-An Chang¹ and Ming‑Han Chen², ¹Division of Allergy, Immunology, Rheumatology/Department of Medicint/Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), ²Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is recognized as a risk factor for osteoporosis. Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) acts as an inhibitory regulator post-T cell activation,…
Abstract Number: 2216 • ACR Convergence 2024
Additive Impact of Rheumatoid Arthritis and HBcAb+ on All-cause and Cardiovascular Mortality
Leiyi Yang¹, Bo Chen², Qibing Xie³ and Geng Yin⁴, ¹Sichuan University, Cheng Du Shi, Sichuan, China (People's Republic), ²Chenbo, Chendu, Sichuan, China, ³Department of Rheumatology and Immunology, Chengdu, Sichuan, China, ⁴Department of Rheumatology and Immunology, chengdu, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) and hepatitis B both have a high incidence and significant health impacts, possibly sharing a pathogenic connection. Notably, a considerable proportion of…
Abstract Number: 2233 • ACR Convergence 2024
Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Susan Manzi⁵, Michael Mahler⁶, Veena Joy⁷ and Tyler O'Malley⁸, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Werfen, San Diego, CA, ⁷ThermoFisher, Philadelphia, PA, ⁸Exagen, Vista, CA
Background/Purpose: Studies have found autoantibodies (Ab) directed against heterogeneous nuclear ribonucleoprotein A2/B1 (anti-RA33), peptidyl arginine deiminase 4 (anti-PAD4) and carbamylated proteins (anti-CarP) each have diagnostic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].